XLO - NASDAQ

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc.

XLOยทNASDAQ

$8.46

-0.71%
HealthcareBiotechnology

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$50.61M
EPS-4.1900
P/E Ratio-21.38
Earnings Date08/13/2026
Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. Fair Value Envelope

XLO ยท NASDAQ

Our analysis suggests that XLO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.46, this represents a potential HIDDEN relative to our calculated worth for Xilio Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $8.46

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.3B
+ Cash & Equivalents$137.5M
Firm Value-$1.2B
- Debt$7.0M
Equity Value-$1.2B
/ Shares Outstanding5,782,510B
DCF Value-$201
OVERVALUED BY 2482%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$8.5M
-$14.4M
-$24.6M
-$41.8M
-$71.0M
-$120.8M
-$205.5M
-$349.5M
-$594.4M
-$1.0B
Maintenance CapEx
-$176.2K
-$299.7K
-$509.7K
-$866.8K
-$1.5M
-$2.5M
-$4.3M
-$7.3M
-$12.3M
-$21.0M
Owner Earnings
-$8.7M
-$14.7M
-$25.1M
-$42.6M
-$72.5M
-$123.3M
-$209.8M
-$356.7M
-$606.7M
-$1.0B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$8.0M
-$12.6M
-$19.9M
-$31.3M
-$49.4M
-$77.7M
-$122.4M
-$192.7M
-$303.5M
-$478.0M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your XLO research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.